Connect with us

Business

Minnesota Omnibus Health Bill Includes Provisions for Psychedelic Task Force

Published

on

Legislators are working on the foundation for the future of psychedelics with the recent passage of an omnibus bill in the Minnesota House.

The Minnesota House of Representatives passed an omnibus health finance bill on April 26 with a 69-58 vote. The bill, SF-2995, contains provisions to create a Psychedelic Medicine Task Force in order to proactively prepare for legalization. The task force would be “established to advise the legislature on the legal, medical, and policy issues associated with the legalization of psychedelic medicine in the state.”

SF-2995 was initially introduced in the Senate in March, and was passed with a third reading on April 19, and received amendments in the House over the past few weeks.

Task force duties include surveying “existing studies in the scientific literature on the therapeutic efficacy of psychedelic medicine in the treatment of mental health conditions, including depression, anxiety, post-traumatic stress disorder, and bipolar disorder, and any other mental health conditions and medical conditions for which a psychedelic medicine may provide an effective treatment option.”

It would also be required to apply necessary changes that apply to “legalization of psychedelic medicine,” “state and local regulation of psychedelic medicine,” and educating the public regarding legislative recommendations.

The task force would include a varied panel of experts, such as the governor and state attorney general, as well as military veterans and others who suffer from mental health conditions.

Should the omnibus bill pass, the task force would be directed to submit two reports to specific individuals who oversee health and human services. The reports would include the task force’s findings, as well as a plan of action to enforce legalization. The first report would be due by Feb. 1, 2024, and the second would need to be submitted no later than Jan. 1, 2025.

When the bill was introduced in February as a standalone bill, it included a requirement for the task force to look into a wide variety of substances. “Psychedelic medicine may include but is not limited to the use of 3,4-methylenedioxymethamphetamine (MDMA), psilocybin, mescaline, LSD, bufotenine, DMT, 5-MeO-DMT, 2C-B, ibogaine, salvinorin A, and ketamine,” the older text stated.

The task force provision would receive $338,000 for fiscal year 2024 and $171,000 in 2025.

Earlier this month, one of the authors of the task force bill, Minnesota Rep. Andy Smith, explained the importance of the bill to KIMT3. “Unfortunately, most of these drugs kind of got wrapped around the world on drugs in the 1980s and so there’s a lot of antiquated laws that are stimming both the research and allowing these drugs to be used in treatment. The goal of the taskforce is to see how we can roll back those regulations well and responsibly,” Smith said. “These drugs . . . have incredible potential to help people who are suffering from depression and at a much cheaper cost. Antidepressants are expensive . . . and these drugs you can usually take them much cheaper.”

While consideration for the omnibus bill is still underway, the Minnesota House just recently passed a cannabis legalization bill on April 25. “It’s time,” said Rep. Zack Stephenson. “Minnesotans deserve the freedom and respect to make responsible decisions about cannabis themselves.”

If passed into law, House File 100 would allow adults over 21 to possess up to two ounces of cannabis flower in public, or 1.5 pounds at home in private. Concentrates would be limited to eight grams, and edibles would be maxed out at no more than 800 mg THC. Residents would also be permitted to grow no more than eight plants at home (with a maximum of four flowering plants).

According to attorney Krissy Atterholt from Vicente Sederberg, there’s high hopes for the future of cannabis in Minnesota. “Minnesota is one step closer to providing residents safe, regulated access to legalized adult-use cannabis,” Atterholt told High Times. “The state is progressing toward becoming the next great cannabis opportunity in the Midwest. Not a single state sharing a border with Minnesota has enacted adult-use cannabis opportunities, leaving the market wide open for businesses and consumers.” 

Source: https://hightimes.com/news/minnesota-omnibus-health-bill-includes-provisions-for-psychedelic-task-force/

Business

New Mexico cannabis operator fined, loses license for alleged BioTrack fraud

Published

on

New Mexico regulators fined a cannabis operator nearly $300,000 and revoked its license after the company allegedly created fake reports in the state’s traceability software.

The New Mexico Cannabis Control Division (CCD) accused marijuana manufacturer and retailer Golden Roots of 11 violations, according to Albuquerque Business First.

Golden Roots operates the The Cannabis Revolution Dispensary.

The majority of the violations are related to the Albuquerque company’s improper use of BioTrack, which has been New Mexico’s track-and-trace vendor since 2015.

The CCD alleges Golden Roots reported marijuana production only two months after it had received its vertically integrated license, according to Albuquerque Business First.

Because cannabis takes longer than two months to be cultivated, the CCD was suspicious of the report.

After inspecting the company’s premises, the CCD alleged Golden Roots reported cultivation, transportation and sales in BioTrack but wasn’t able to provide officers who inspected the site evidence that the operator was cultivating cannabis.

In April, the CCD revoked Golden Roots’ license and issued a $10,000 fine, according to the news outlet.

The company requested a hearing, which the regulator scheduled for Sept. 1.

At the hearing, the CCD testified that the company’s dried-cannabis weights in BioTrack were suspicious because they didn’t seem to accurately reflect how much weight marijuana loses as it dries.

Company employees also poorly accounted for why they were making adjustments in the system of up to 24 pounds of cannabis, making comments such as “bad” or “mistake” in the software, Albuquerque Business First reported.

Golden Roots was fined $298,972.05 – the amount regulators allege the company made selling products that weren’t properly accounted for in BioTrack.

The CCD has been cracking down on cannabis operators accused of selling products procured from out-of-state or not grown legally:

Golden Roots was the first alleged rulebreaker in New Mexico to be asked to pay a large fine.

Source: https://mjbizdaily.com/new-mexico-cannabis-operator-fined-loses-license-for-alleged-biotrack-fraud/

Continue Reading

Business

Marijuana companies suing US attorney general in federal prohibition challenge

Published

on

Four marijuana companies, including a multistate operator, have filed a lawsuit against U.S. Attorney General Merrick Garland in which they allege the federal MJ prohibition under the Controlled Substances Act is no longer constitutional.

According to the complaint, filed Thursday in U.S. District Court in Massachusetts, retailer Canna Provisions, Treevit delivery service CEO Gyasi Sellers, cultivator Wiseacre Farm and MSO Verano Holdings Corp. are all harmed by “the federal government’s unconstitutional ban on cultivating, manufacturing, distributing, or possessing intrastate marijuana.”

Verano is headquartered in Chicago but has operations in Massachusetts; the other three operators are based in Massachusetts.

The lawsuit seeks a ruling that the “Controlled Substances Act is unconstitutional as applied to the intrastate cultivation, manufacture, possession, and distribution of marijuana pursuant to state law.”

The companies want the case to go before the U.S. Supreme Court.

They hired prominent law firm Boies Schiller Flexner to represent them.

The New York-based firm’s principal is David Boies, whose former clients include Microsoft, former presidential candidate Al Gore and Elizabeth Holmes’ disgraced startup Theranos.

Similar challenges to the federal Controlled Substances Act (CSA) have failed.

One such challenge led to a landmark Supreme Court decision in 2005.

In Gonzalez vs. Raich, the highest court in the United States ruled in a 6-3 decision that the commerce clause of the U.S. Constitution gave Congress the power to outlaw marijuana federally, even though state laws allow the cultivation and sale of cannabis.

In the 18 years since that ruling, 23 states and the District of Columbia have legalized adult-use marijuana and the federal government has allowed a multibillion-dollar cannabis industry to thrive.

Since both Congress and the U.S. Department of Justice, currently headed by Garland, have declined to intervene in state-licensed marijuana markets, the key facts that led to the Supreme Court’s 2005 ruling “no longer apply,” Boies said in a statement Thursday.

“The Supreme Court has since made clear that the federal government lacks the authority to regulate purely intrastate commerce,” Boies said.

“Moreover, the facts on which those precedents are based are no longer true.”

Verano President Darren Weiss said in a statement the company is “prepared to bring this case all the way to the Supreme Court in order to align federal law with how Congress has acted for years.”

While the Biden administration’s push to reschedule marijuana would help solve marijuana operators’ federal tax woes, neither rescheduling nor modest Congressional reforms such as the SAFER Banking Act “solve the fundamental issue,” Weiss added.

“The application of the CSA to lawful state-run cannabis business is an unconstitutional overreach on state sovereignty that has led to decades of harm, failed businesses, lost jobs, and unsafe working conditions.”

Source: https://mjbizdaily.com/marijuana-companies-suing-us-attorney-general-to-overturn-federal-prohibition/

Continue Reading

Business

Alabama to make another attempt Dec. 1 to award medical cannabis licenses

Published

on

Alabama regulators are targeting Dec. 1 to award the first batch of medical cannabis business licenses after the agency’s first two attempts were scrapped because of scoring errors and litigation.

The first licenses will be awarded to individual cultivators, delivery providers, processors, dispensaries and state testing labs, according to the Alabama Medical Cannabis Commission (AMCC).

Then, on Dec. 12, the AMCC will award licenses for vertically integrated operations, a designation set primarily for multistate operators.

Licenses are expected to be handed out 28 days after they have been awarded, so MMJ production could begin in early January, according to the Alabama Daily News.

That means MMJ products could be available for patients around early March, an AMCC spokesperson told the media outlet.

Regulators initially awarded 21 business licenses in June, only to void them after applicants alleged inconsistencies with how the applications were scored.

Then, in August, the state awarded 24 different licenses – 19 went to June recipients – only to reverse themselves again and scratch those licenses after spurned applicants filed lawsuits.

A state judge dismissed a lawsuit filed by Chicago-based MSO Verano Holdings Corp., but another lawsuit is pending.

Source: https://mjbizdaily.com/alabama-plans-to-award-medical-cannabis-licenses-dec-1/

Continue Reading

Trending

Copyright © 2022 420 Reports Marijuana News & Information Website | Reefer News | Cannabis News